Esperion Therapeutics Inc. (NASDAQ:ESPR)’s share price fell 2.1% on Thursday . The company traded as low as $10.63 and last traded at $10.65, with a volume of 152,444 shares traded. The stock had previously closed at $10.88.

Several research firms recently commented on ESPR. Chardan Capital reiterated a “hold” rating and issued a $13.00 price objective on shares of Esperion Therapeutics in a research report on Wednesday, June 29th. Barclays PLC lowered shares of Esperion Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $28.00 to $13.00 in a research report on Wednesday, June 29th. Vetr lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating and set a $12.60 price objective on the stock. in a research report on Monday, July 18th. Needham & Company LLC reiterated a “buy” rating and issued a $25.00 price objective (down from $77.00) on shares of Esperion Therapeutics in a research report on Wednesday, June 29th. Finally, Stifel Nicolaus lowered shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and decreased their price objective for the stock from $23.00 to $10.00 in a research report on Thursday, June 30th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $24.40.

The company’s 50-day moving average price is $10.97 and its 200-day moving average price is $14.83. The company’s market capitalization is $236.78 million.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.16. During the same period in the prior year, the company posted ($0.55) earnings per share. On average, analysts forecast that Esperion Therapeutics Inc. will post ($3.36) earnings per share for the current year.

In other Esperion Therapeutics news, Director Mark E. Mcgovern purchased 5,000 shares of the stock in a transaction on Wednesday, July 6th. The stock was bought at an average cost of $10.00 per share, for a total transaction of $50,000.00. Following the completion of the acquisition, the director now directly owns 600 shares of the company’s stock, valued at $6,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

An institutional investor recently raised its position in Esperion Therapeutics stock. Schwab Charles Investment Management Inc. raised its stake in Esperion Therapeutics Inc. (NASDAQ:ESPR) by 3.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 45,549 shares of the biopharmaceutical company’s stock after buying an additional 1,413 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.20% of Esperion Therapeutics worth $1,014,000 as of its most recent SEC filing.

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.